Although patients with unresectable, metastatic, or recurrent RCC have poor prognoses, the recent development of immune checkpoint inhibitors (ICIs), such as programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1) inhibitors, as well as antivascular endothelial growth factor‐targeted therapy have improved their outcomes [2, 3]. Here, CD274 is linked to renal cell adenocarcinoma.